Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 3 study of setrusumab in pediatric Japanese subjects with osteogenesis imperfecta types I, III, or IV
jRCT2051240133Phase 3Active, not recruiting
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of setrusumab in Osteogenesis imperfecta type I, Osteogenesis imperfecta type III and osteogenesis imperfecta type 4 (OI-IV), sponsored by Ultragenyx Pharmaceutical Inc. Primary endpoint: Annualized rate of all radiographically-confirmed fractures during the Treatment Period. Started Oct 2024; status: active, not recruiting.
02
Drugs
setrusumab
03
Conditions
Osteogenesis imperfecta type IOsteogenesis imperfecta type IIIosteogenesis imperfecta type 4 (OI-IV)
Beyond the preview
Go deeper on jRCT2051240133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240133.